Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19

Clinical, control, double-blind, randomized trial with tenofovir disoproxyl fumarate and emtricitabine for Covid-19

  • 0 views
  • 01 Feb, 2021
  • 1 location
A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (DEFINE)

The purpose of this study is to assess the percent change in body weight when switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC

  • 236 views
  • 30 Apr, 2022
  • 34 locations
Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

To evaluate the safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus tenofovir disoproxil fumarate-based antiretroviral regimens in HIV-infected individuals with

  • 0 views
  • 12 Mar, 2022
  • 2 locations
  • 0 views
  • 26 Jan, 2021
  • 1 location
Study to Assess Switching to B/F/TAF in Treatment Experienced People With HIV Who Are at Least 65 Years of Age

/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination regimen.

  • 0 views
  • 13 Dec, 2021
  • 1 location
Combination Antiretroviral Therapy (cART) for PBC

will be performed in parallel using Emtricitabine (FTC)/Tenofovir Disoproxil (TDF) & Raltegravir in liver transplant recipients meeting all entry criteria except for use of immunosuppression.

  • 16 views
  • 25 Apr, 2022
  • 1 location
Dolutegravir-Lamivudine for na ve HIV-Infected Patients With 200 CD4/mm3

Protocol Title: DOLCE: Dolutegravir-Lamivudine for nave HIV-Infected Patients with 200 CD4/mm3 Protocol Number: FH-57 Study Objectives: To assess the antiviral activity at week 48 of DTG+3TC among nave HIV patients with a CD4 count 200 cells /mm3.

  • 0 views
  • 04 Oct, 2021
  • 4 locations
Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum

The purpose of this study is to evaluate the pharmacokinetics, feasibility, acceptability, and safety of a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as

emtricitabine/ tenofovir disoproxil fumarate
HIV Vaccine
drug levels
tenofovir
Accepts healthy volunteers
  • 142 views
  • 05 Mar, 2022
  • 5 locations
Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)

The study ANRS 174 Doxyvac is a clinical trial that will use Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men and using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP) and vaccination with Bexsero.

  • 0 views
  • 25 Mar, 2021
  • 9 locations
Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants

(6 to < 12 years of age) To evaluate the steady-state PK of tenofovir alafenamide (TAF) and confirm the dose of emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected pediatric

antiretroviral agents
atazanavir
darunavir
emtricitabine/tenofovir
cobicistat
  • 292 views
  • 23 Apr, 2022
  • 9 locations